About the 2022 POPIA Program

Overview

Three grants will be awarded in 2022 to support initiatives and collaborative programs designed to help people with certain cancers access precision oncology care. Programs may be relevant to pediatric or adult cancer communities.


The 2022 awards will be appointed to innovative programs tackling access to biomarker testing in the following cancer types:

lung cancer

Lung Cancer

lung cancer

Thyroid Cancer

lung cancer

Rarer Cancer Types such as pediatric cancers, sarcomas, and other solid tumors that are known to harbor rare, actionable genomic alterations. Types of genomic alterations can include KRAS, HER2, BRAF, EGFR, ALK, ROS1, NTRK gene fusions, and many more

Apply for the Precision Oncology Patient Innovation Awards

View more details on how to apply


Next Important Date

June 10, 2022 – Deadline for initial applications

Submissions must be received no later than 12:00 AM (midnight) EDT

See all important dates and deadlines

Applications will be reviewed by an independent, non-Bayer review panel composed of experienced representatives from the clinical and patient advocacy communities.

Duration of Award: 1 Year

Award Value: Three awards in the amount of $30,000 each (US dollars)

2022 POPIA Program Timeline

Action Dates
Applications open April 25, 2022
Deadline for entries June 10, 2022
Applications reviewed by REVIEW PANEL June 2022
Applicants chosen to submit a full proposal June 27, 2022
Full Proposal submission deadline July 15, 2022
Applicants notified of decision August 1, 2022
winning programs announced during esmo 2022  September 9-13, 2022 

Apply for the Precision Oncology Patient Innovation Awards

View more details on how to apply


Next Important Date

June 10, 2022 – Deadline for initial applications

Submissions must be received no later than 12:00 AM (midnight) EDT

See all important dates and deadlines
    lung cancer

    Improve access to tumor testing to inform patient diagnosis and care

    Playbook icon

    Address inequalities and barriers in precision medicine that impact cancer communities

     

    Lightbulb Icon

    Improve community education, training, and awareness in precision medicine, including tumor tissue testing for genomic and oncogenic drivers

      Applications will be accepted from nonprofit organizations, including patient advocacy groups, educational institutions, and officially recognized healthcare/research facilities from around the world, unless prohibited by national law.

       

      Applications from individuals will not be allowed.

       

      Collaborations between institutions, including between patient groups and research facilities, are welcome.

       

      Please designate a lead organization in the application.

       

      Learn more about the application process

        You may apply to support a new initiative or to support the continued rollout/expansion of an existing program. Applying for the grant does not preclude you from seeking other sources of funding. Although the award is for 1 year, your program can continue beyond the year.

        Initiatives should be focused on precision oncology and may include, but are not limited to:

        • Health intervention programs such as a community testing or community training program
        • Testing algorithm tool
        • Survey
        • Communications tool (eg, help to interpret complex information on cancer type or tests)
        • Public health initiative
        • Education resources for healthcare professionals or patients/care partners (eg, online tool, infographic, website, animation, events, printed materials)
        • Awareness campaign
        • Digital health/technology project publication

        Interventional clinical trials and translational research studies are not included in the awards.

         

        Bayer provides other forms of scientific partnership in focused areas of research, which are listed on its corporate website.

          The grant amount requested in funding cannot exceed 25% of an organization’s overall funding.

           

          Program must be nonpromotional and should not include mention of any particular medicine. Program may refer to class of treatment.

           

          Program should be initiated within 1 year of receiving funds, and metrics should be reported by an agreed-upon date.

           

          Applications should comply with program criteria.

            Successful applicants will be announced publicly. Bayer will make every effort to help successful applicants share their programs with the wider cancer community.